Outlook Therapeutics Inc OTLK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OTLK is a good fit for your portfolio.
News
-
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
-
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
-
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
-
Thinking about buying stock in Mind Medicine, Ocean Biomedical, Archer Aviation, Outlook Therapeutics, or Cardiff Oncology?
-
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
-
Kaskela Law LLC Announces Shareholder Investigation of Outlook Therapeutics, Inc. (OTLK) and Encourages Investors to Contact the Firm
-
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corporate Update
-
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
Trading Information
- Previous Close Price
- $8.19
- Day Range
- $8.14–8.50
- 52-Week Range
- $4.00–40.60
- Bid/Ask
- $8.14 / $8.44
- Market Cap
- $196.41 Mil
- Volume/Avg
- 120,913 / 674,247
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 24
Comparables
Valuation
|
Metric
|
OTLK
|
EQRX
|
CGEM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 0.97 | 2.39 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
OTLK
|
EQRX
|
CGEM
|
|---|---|---|---|
Quick Ratio | 0.23 | 18.43 | 16.60 |
Current Ratio | 0.44 | 18.78 | 17.07 |
Interest Coverage | — | — | — |
Quick Ratio
OTLK
EQRX
CGEM
Profitability
|
Metric
|
OTLK
|
EQRX
|
CGEM
|
|---|---|---|---|
Return on Assets (Normalized) | −109.66% | −15.72% | −24.60% |
Return on Equity (Normalized) | — | −16.71% | −25.95% |
Return on Invested Capital (Normalized) | −157.51% | −21.31% | −29.67% |
Return on Assets
OTLK
EQRX
CGEM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qslblzjfx | Rtlp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kfnwtwjc | Tnykhm | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mpwykbvy | Hzyvh | $97.8 Bil | |
MRNA
| Moderna Inc | Hrzsbjp | Hgshd | $41.3 Bil | |
ARGX
| argenx SE ADR | Cgxwfrc | Wzggn | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Xvlthkyvf | Gfks | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Qgzcxcgl | Hktjnz | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fmyzcts | Vvnlbj | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Glfrbnzm | Pmzghr | $12.5 Bil | |
INCY
| Incyte Corp | Rxxjkvtp | Tvvhz | $11.6 Bil |